Biopharmaceutics & Drug Disposition 2015-01-01

Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.

Mikiko Tsukimoto, Rikiya Ohashi, Nao Torimoto, Yoko Togo, Takashi Suzuki, Toshio Maeda, Yoshiyuki Kagawa

Index: Biopharm. Drug Dispos. 36(1) , 15-33, (2015)

Full Text: HTML

Abstract

Aliskiren is a substrate for P-glycoprotein (P-gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P-gp influenced the pharmacokinetics of aliskiren and also if drug-drug interactions (DDIs) mediated through P-gp could be reproduced in cynomolgus monkeys. The study investigated the pharmacokinetics of aliskiren in mdr1a/1b gene-deficient (P-gp KO) and wild-type (WT) mice. The area under the plasma concentration-time curve (AUC) following the oral administration of aliskiren was 6.9-fold higher in P-gp KO mice than in WT mice, while no significant differences were observed in the AUC or total plasma clearance following the intravenous administration of aliskiren to P-gp KO mice. Then the pharmacokinetics of aliskiren were evaluated and DDIs between aliskiren and P-gp inhibitors, such as cyclosporin A (CsA) and zosuquidar, examined in cynomolgus monkeys. The AUC for aliskiren were 8.3- and 42.1-fold higher after the oral administration of aliskiren with the concomitant oral administration of zosuquidar and CsA at doses of 10 and 30 mg/kg, respectively. In contrast, the AUC after the intravenous and oral administration of aliskiren was not significantly affected by the oral administration of zosuquidar or intravenous administration of CsA, respectively. These results indicated that P-gp strictly limited the intestinal absorption of aliskiren in mice and monkeys, and also that the effects of intestinal P-gp inhibition by CsA or zosuquidar on the pharmacokinetics of aliskiren were sensitively reproduced in monkeys. In conclusion, aliskiren can be used as a sensitive substrate to evaluate intestinal P-gp inhibition in monkeys.Copyright © 2014 John Wiley & Sons, Ltd.

Related Compounds

Structure Name/CAS No. Articles
Ketoconazole Structure Ketoconazole
CAS:65277-42-1
Erythromycin Structure Erythromycin
CAS:114-07-8
Cyclosporin A Structure Cyclosporin A
CAS:59865-13-3
Ethylene glycol Structure Ethylene glycol
CAS:107-21-1
Colchicine Structure Colchicine
CAS:64-86-8
Quinidine sulfate dihydrate Structure Quinidine sulfate dihydrate
CAS:6591-63-5
Carbamazepine Structure Carbamazepine
CAS:298-46-4
1,1-Diethoxyethane Structure 1,1-Diethoxyethane
CAS:105-57-7